Welcome to our dedicated page for Kalvista Pharm SEC filings (Ticker: KALV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
KalVista Pharmaceuticals SEC filings document 8-K disclosures for a commercial-stage pharmaceutical company focused on oral rare-disease therapies. The filings cover results of operations and financial condition, Regulation FD materials, product-revenue updates tied to EKTERLY, and the company’s Nasdaq-listed common stock.
The filing record also includes governance and compensation disclosures, board committee changes, executive appointments, material definitive agreements, and capital-structure actions. Financing disclosures include the completed sale of 3.250% convertible senior notes due 2031, while other reports describe exhibit filings, furnished press releases, Inline XBRL cover data, and formal disclosure treatment under the Exchange Act.
KalVista Pharmaceuticals reported results for the eight-month transition period ended December 31, 2025, reflecting its shift to a calendar fiscal year. The company generated $49.1 million in global net product revenue from EKTERLY, the first and only oral on-demand treatment for hereditary angioedema.
Adoption is highlighted by 1,702 US patient start forms from launch through February and launches in markets including Germany and Japan through partner Kaken. Despite this growth, KalVista reported a net loss of $109.5 million and basic and diluted net loss per share of $2.03 for the period.
On the balance sheet, cash, cash equivalents and marketable securities were $300.2 million as of December 31, 2025, with total assets of $335.4 million and total liabilities of $338.1 million, resulting in a modest stockholders’ deficit. Management reiterated plans to expand EKTERLY access and advance pediatric filings.
KalVista Pharmaceuticals CEO Benjamin L. Palleiko reported routine equity compensation activity and a related tax sale. On March 6, 2026, he exercised 15,625 Restricted Stock Units (RSUs), receiving an equal number of KalVista common shares for no cash consideration. The RSUs vest in 16 equal quarterly installments starting June 6, 2024, subject to continued service. On March 9, 2026, he sold 6,693 common shares at a weighted average price of $16.0814 per share solely to cover tax withholding obligations from the RSU vesting, described as a non-discretionary “sell to cover” transaction. After these transactions, he holds 451,815 common shares directly and 125,001 RSUs, giving him a substantial ongoing equity stake.
KalVista Pharmaceuticals chief medical officer Paul K. Audhya reported a mix of equity award vesting and tax-related share sales. He exercised and settled restricted stock units (RSUs) into 6,250 and 5,000 shares of common stock at no cost on separate days, reflecting routine equity compensation vesting where each RSU converts into one share.
To cover tax withholding from these RSU settlements, he sold 5,354 shares of common stock in an open-market "sell to cover" transaction at a weighted average price of $15.5668 per share, described as non-discretionary. After these transactions, he held 138,983 shares of common stock directly, with RSU awards continuing to vest in equal sixteenth installments on each quarterly anniversary of the vesting commencement date.
KalVista Pharmaceuticals CEO Benjamin L. Palleiko reported a mix of RSU vesting and tax-related share sales. On February 21, 2026, he acquired 23,250 shares of Common Stock at $0.00 per share through the settlement of Restricted Stock Units, each RSU converting into one common share at no cost.
On February 23, 2026, he sold 10,034 shares of Common Stock at a weighted average price of $15.5668 per share, in transactions ranging from $15.5253 to $15.566982. According to the disclosure, this sale was a mandatory “sell to cover” to satisfy tax withholding obligations tied to the RSU vesting, and was not a discretionary trade.
KalVista Pharmaceuticals’ Chief Development Officer Christopher Yea reported RSU vesting, share issuance, and a related tax sale of common stock. On February 21 and 22, RSUs covering a total of 6,875 restricted stock units were exercised into the same number of common shares for no cash consideration.
Following these conversions, Yea conducted an open‑market "sell to cover" transaction on February 23, disposing of 4,347 common shares at a weighted average price of $15.5668 per share solely to satisfy tax withholding obligations tied to the RSU vesting. After these transactions, he held 226,701 common shares and 28,125 RSUs directly, with future RSU vesting scheduled in quarterly installments.
KalVista Pharmaceuticals Chief Commercial Officer Nicole Sweeny reported RSU vesting and related share movements. She acquired 6,250 and 5,000 shares of common stock on derivative exercises of restricted stock units at a price of $0.0000 per share. Each RSU represents a right to receive one share of common stock, with 1/16th of the award vesting on each quarterly anniversary of the vesting commencement date, subject to continued service.
On a separate transaction, she sold 3,975 shares of common stock in an open-market sale at a weighted average price of $15.5668 per share, in multiple trades between $15.5101 and $15.566982. The filing states this sale was a "sell to cover" to satisfy tax withholding obligations arising from RSU vesting and was not a discretionary transaction. Following these transactions, she directly held 47,003 shares of KalVista common stock.
KalVista Pharmaceuticals Chief Financial Officer Brian Piekos reported RSU vesting and a related tax sale. On February 21, 2026, he acquired 5,000 shares of Common Stock at $0.00 per share through the exercise and settlement of 5,000 Restricted Stock Units, each RSU converting into one share for no consideration. On February 23, 2026, he sold 1,767 shares of Common Stock in open-market transactions at a weighted-average price of $15.5668 per share to cover tax withholding obligations under a non-discretionary sell-to-cover arrangement. Following these transactions, he directly held 13,762 shares of Common Stock and 60,000 RSUs.
KalVista Pharmaceuticals chief executive officer Benjamin L. Palleiko reported routine equity compensation activity. On February 17, he exercised 2,419 restricted stock units, each converting into one share of common stock for no cash consideration, and his common stock holdings increased to 430,705 shares.
On February 18, he sold 1,038 common shares at $15.00 per share solely to cover tax withholding obligations related to the RSU vesting, a non‑discretionary “sell to cover” transaction. After this tax sale, he directly owned 429,667 common shares and 2,419 RSUs subject to continued vesting in equal quarterly installments.
KalVista Pharmaceuticals chief medical officer Paul K. Audhya reported routine equity transactions linked to restricted stock units (RSUs). He sold 1,163 shares of common stock at $15.00 per share to cover tax withholding obligations arising from RSU vesting in a non-discretionary sell-to-cover trade.
In connection with this, 2,419 RSUs were exercised and converted into 2,419 shares of common stock for no cash consideration, with each RSU representing one share upon settlement. The RSUs vest in equal sixteenth installments on each quarterly anniversary of the vesting commencement date, subject to continued service.
KalVista Pharmaceuticals chief development officer Christopher Yea reported RSU vesting and related share activity. On February 17, 2026, 1,774 restricted stock units were converted into 1,774 shares of common stock for no cash consideration. On February 18, 2026, 1,109 common shares were sold at $15.00 per share solely to cover tax withholding obligations under a pre-arranged “sell to cover” and were not a discretionary sale.